Expres2ion Biotech Holding AB (EXPRS2) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Flat results in Mar 25

NET SALES(9M) At SEK 2.39 MM has Grown at -31.44%
INTEREST(HY) At SEK 0.61 MM has Grown at 127.44%
NET PROFIT(Q) At SEK -11.44 MM has Fallen at -25.66%

Risky -

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

SEK 66 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.13

Return on Equity

-111.78%

Price to Book

1.55

Revenue and Profits:

Net Sales:

1 Million

(Quarterly Results - Mar 2025)

Net Profit:

-11 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-24.42%

6 Months

-26.29%

1 Year

-12.67%

2 Years

-68.44%

3 Years

-96.02%

4 Years

-98.9%

5 Years

-94.47%

Expres2ion Biotech Holding AB for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-22.00%

EBIT Growth (5y)

-206.19%

EBIT to Interest (avg)

-72.92

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.13

Sales to Capital Employed (avg)

0.08

Tax Ratio

13.20%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.24

EV to EBIT

-0.07

EV to EBITDA

-0.07

EV to Capital Employed

-0.76

EV to Sales

1.11

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-111.78%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

No Trend

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is 116.67% vs 20.00% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is 26.92% vs -48.57% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.30",
          "val2": "0.60",
          "chgp": "116.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-13.90",
          "val2": "-20.90",
          "chgp": "33.49%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.50",
          "val2": "0.10",
          "chgp": "400.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-11.40",
          "val2": "-15.60",
          "chgp": "26.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-10,726.70%",
          "val2": "-35,524.20%",
          "chgp": "2,479.75%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -57.14% vs 37.25% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 60.61% vs 22.93% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3.00",
          "val2": "7.00",
          "chgp": "-57.14%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-70.90",
          "val2": "-106.10",
          "chgp": "33.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.70",
          "val2": "0.50",
          "chgp": "40.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-36.00",
          "val2": "-91.40",
          "chgp": "60.61%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-24,064.70%",
          "val2": "-15,278.60%",
          "chgp": "-878.61%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ

Mar'25

Dec'24

Change(%)

Net Sales

1.30

0.60

116.67%

Operating Profit (PBDIT) excl Other Income

-13.90

-20.90

33.49%

Interest

0.50

0.10

400.00%

Exceptional Items

0.00

Consolidate Net Profit

-11.40

-15.60

26.92%

Operating Profit Margin (Excl OI)

-10,726.70%

-35,524.20%

2,479.75%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Mar 2025 is 116.67% vs 20.00% in Dec 2024

Consolidated Net Profit

QoQ Growth in quarter ended Mar 2025 is 26.92% vs -48.57% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

3.00

7.00

-57.14%

Operating Profit (PBDIT) excl Other Income

-70.90

-106.10

33.18%

Interest

0.70

0.50

40.00%

Exceptional Items

0.00

Consolidate Net Profit

-36.00

-91.40

60.61%

Operating Profit Margin (Excl OI)

-24,064.70%

-15,278.60%

-878.61%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -57.14% vs 37.25% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 60.61% vs 22.93% in Dec 2023

All Annual Results

Company CV

About Expres2ion Biotech Holding AB

Expres2ion Biotech Holding AB

Pharmaceuticals & Biotechnology

ExpreS2ion Biotech Holding AB is a Sweden-based biopharmaceutical company. The Company specializes in developing cell lines and processes based on a non-viral Drosophila S2 cells expression system. The Company's ExpreS2 recombinant protein expression platform supports all phases of drug discovery, research and development and manufacturing. ExpreS2 is a non-viral insect cell expression system that establishes stable polyclonal pools that provide high-protein expression levels without selection pressure. The system is designed for transient or stable transfections using vector deoxyribonucleic acid containing a hybrid promoter. It also ensures high cell density without aggregation or toxic metabolite build-up issues. Through the joint venture AdaptVac ApS, the Company applies a Plug-and-Play Virus Like Particle technology for development of therapeutic and prophylactic vaccines within oncology, infectious diseases and immunological disorders.

Company Coordinates

Company Details

Ronnowsgatan 8 C , HELSINGBORG None : 252 25

Tel:

Registrar Details